Vesiculab’s Post

Investigating plasma- and adipose-derived MSC-EVs as potential therapeutic platforms for neuroinflammation: in this recent article, Rummenigge Oliveira Silva, Charles Ramassamy at INRS-Institut Armand-Frappier and collaborators demonstrated that human plasma-derived EVs exhibit greater brain-targeting specificity, while adipose-derived mesenchymal stem cell EVs provide regenerative and immunomodulatory benefits. They further explored the potential of these EVs as therapeutic carriers for brain-targeted drug delivery using Donepezil (DNZ), a cholinesterase inhibitor with neuroprotective and anti-inflammatory properties commonly used for Alzheimer's disease https://lnkd.in/gxnxE_45 In vivo experiments with zebrafish larvae showed that both EV formulations reduced microglial proliferation and exhibited antioxidant effects. Their findings highlight the promise of DNZ-loaded EVs as a novel strategy for treating neuroinflammation associated with neurodegenerative diseases. An article co-authored by Mohamed Haddad, Hermine Counil, Charlotte Zaouter, Shunmoogum Patten and Tamas Fulop #extracellularvesicles #exosomes #MSCs #drugdelivery #neuroinflammation #Vesiculab